Repligen Stock News

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

— Record revenue of $186.5 million for the quarter, and year-over-year growth of 72%

Repligen (RGEN) CEO, Tony Hunt on Q4 2021 Results - Earnings Call Transcript

Repligen (RGEN) delivered earnings and revenue surprises of 24.62% and 3.78%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Companies Reporting Before The Bell • Palantir Technologies (NYSE: PLTR ) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. • Organon (NYSE: OGN ) is expected to report quarterly earnings at $1.24 per share on revenue of $1.57 billion. • Perella Weinberg Partners (NASDAQ: PWP ) is likely to report quarterly earnings at $0.30 per share on revenue of $193.75 million. • Navios Maritime Partners (NYSE: NMM ) is estimated to report quarterly earnings at $4.35 per share on revenue of $272.59 million. • Portland General Electric (NYSE: POR ) is likely to report quarterly earnings at $0.76 per share on revenue of $533.13 million. • Frontline (NYSE: FRO ) is estimated to report quarterly earnings at $0.13 per share on revenue of $111.30 million. • R1 RCM (NASDAQ: RCM ) is estimated to report quarterly earnings at $0.11 per share on revenue of $399.26 million. • Fiverr International (NYSE: FVRR ) is likely to report quarterly earnings at $0.04 per share on revenue of $76.

Repligen (NASDAQ:RGEN) is scheduled to announce Q4 earnings results on Thursday, Feb. 17, before market open.The consensus EPS estimate is $0.65 (+25% Y/Y)

Let us take a look at four biotech or drug companies - RGEN, IRWD, EXEL and LGND - due to release their quarterly results on Feb 16.

Repligen (RGEN) launched three advanced affinity chromatography resins for use in gene therapy manufacturing workflows.The company said the resins — AVIPure - AAV9, AVIPure - AAV8,…

AVIPure® affinity resins address the market need for high performance and caustic stability AVIPure® affinity resins address the market need for high performance and caustic stability

Sector ETF report for PBE

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate

Repligen Corporation (NASDAQ:RGEN)s traded shares stood at 0.33 million during the last session, with the companys beta value hitting 0.91. At the close of trading, the stocks price was $188.97, to imply a decrease of -2.49% or -$4.82 in intraday trading. The RGEN shares 52-week high remains $327.32, putting it -73.21% down since that peak After The Stock Fell -5.96% Over The Week, Is Repligen Corporation (NASDAQ: RGEN) Still A Buy? Read More »

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present vir

WALTHAM, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN ), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at the 11th Annual SVB Leerink Healthcare Conference being held Feb. 14-18, 2022. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Friday, Feb. 18, at 3:00 p.m. EST. A live webcast of the presentation will be accessible through Repligen''s Full story available on Benzinga.com